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Abstract 
Advanced liver fibrosis in nonalcoholic steatohepatitis (NASH) is often accompanied by a reduction 
in hepatic fat to the point of complete fat loss (burnt-out NASH), but the mechanisms behind this 
phenomenon have not been elucidated. Adiponectin is raised in cirrhosis of any cause and has 
potent antisteatotic activity. In this study we examined 65 patients with advanced biopsy-proven 
NASH (fibrosis stage 3-4) and 54 with mild disease (fibrosis stage 0-1) to determine if 
disappearance of steatosis correlated with changes in serum adiponectin. All patents had fasting 
blood tests and anthropometric measures at the time of liver biopsy. Liver fat was accurately 
quantitated by morphometry. Serum adiponectin was measured by immunoassay. When 
compared to those with early disease, patients with advanced NASH were more insulin-resistant, 
viscerally obese, and older, but there was no difference in liver fat content or adiponectin levels. 
Adiponectin had a significant negative correlation with liver fat percentage in the whole cohort (r = 
−0.28, P < 0.01), driven by patients with advanced NASH (r = −0.40, P < 0.01). In advanced NASH, 
for each 4 μg/L increase in adiponectin there was an odds ratio OR of 2.0 (95% confidence interval 
[CI]: 1.3-3.0, P < 0.01) for a 5% reduction in hepatic fat. Adiponectin was highly and significantly 
associated with almost complete hepatic fat loss or burnt-out NASH (12.1 versus 7.4 μg/L, P = 
0.001) on multivariate analysis. A relationship between adiponectin, bile acids, and adipocyte 
fexaramine activation was demonstrated in vivo and in vitro, suggestive of hepatocyte-adipocyte 
crosstalk. Conclusion: Serum adiponectin levels in advanced NASH are independently associated 
with hepatic fat loss. Adiponectin may in part be responsible for the paradox of burnt-out NASH.  
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Introduction 
Nonalcoholic steatohepatitis (NASH) is characterized histologically by hepatic steatosis, 
inflammation, ballooning of hepatocytes, and liver fibrosis.1 Hepatic steatosis, or fat, is considered 
intrinsic to the disorder, and a sine qua non of the most commonly used disease classifications.2-4 
It is therefore somewhat of a paradox, and an intriguing but well-replicated observation, that in 
advanced fibrotic NASH the disease in some patients appears to “burn out” with liver histology 
revealing little or no discernable fat.5-7 Indeed, in the 20 years since NASH was first recognized as a 
common cause of cryptogenic cirrhosis,7 further studies have shown NASH to be responsible for 
the majority of such cases,5, 6 and diagnostic algorithms have been created accordingly.8, 9 A 
number of putative mechanisms have been proposed to explain the loss of hepatic fat in advanced 
NASH including portosystemic shunting,10 changes in mitochondrial metabolism,8 vascular 
changes,11 and the inflammatory, catabolic state associated with cirrhosis.12 The exact 
mechanisms behind this phenomenon, however, have not been elucidated. 
Adiponectin, the most abundant human adipocytokine, is intimately associated with hepatic 
steatosis, acting directly on hepatocytes to upregulate fatty acid oxidation, inhibit fatty acid 
synthesis, and to improve insulin sensitivity.13 In obese mice adiponectin treatment is associated 
with resolution of hepatic steatosis and hepatomegaly,13 whereas in humans treatment with 
peroxisome proliferator-activated receptor (PPAR)-gamma ligands such as pioglitazone increase 
adiponectin levels and reduce liver fat.14 As expected, adiponectin levels are inversely correlated 
with steatosis and necroinflammation in NASH, but the relationship with fibrosis is less clear-cut.15, 
16 Adiponectin is increased in cirrhosis of any cause and, importantly, levels incrementally increase 
between fibrosis stages 3 and 4, as well as Child's stages A and B.15, 17, 18 Furthermore, adiponectin 
levels in established cirrhosis are independent of body mass index (BMI) and insulin resistance, but 
rather, correlate with markers of liver synthetic dysfunction and cholestasis.17, 18Given these 
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observations (fat loss in advanced disease and reports of elevated circulating adiponectin with 
progressive hepatic fibrosis), we surmised that adiponectin may in part explain hepatic fat loss in 
late-stage NASH. To test this hypothesis we measured serum adiponectin in 65 NASH patients with 
advanced fibrosis (fibrosis stage [F]3-4) and a similar number with early disease (F0-1). Because 
liver histology is semiquantitative, we further examined the relationship between serum 
adiponectin and accurate quantification of hepatic fat using morphometry of whole liver biopsy 
cores. We found that adiponectin is independently associated with hepatic fat loss in late stage, 
compensated NASH and that it is the only independent predictor of burnt-out NASH. Further, we 
suggest the novel concept that bile acid-mediated hepatocyte-adipocyte crosstalk may mediate 
the elevations in serum adiponectin in advanced fibrotic liver disease. 
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Materials and Methods 
Patients and Data Collection. 
We performed a cross-sectional study on 119 adults with biopsy-proven NASH recruited from 
tertiary liver clinics at Westmead Hospital, Sydney Australia, and the University of Turin Italy. From 
prospectively collected databases of over 800 consecutive patients, 65 patients with advanced 
NASH (F3 or 4), had stored serum and liver tissue available for analysis. They were compared to 54 
consecutive patients with mild NASH (F0 or 1). Patients with intermediate stage fibrosis (F2) were 
excluded to ensure a valid comparison between early and advanced disease. Patients were 
referred for the assessment of abnormal liver tests or hepatic steatosis detected by 
ultrasonography. In all patients, current and past daily alcohol intake was less than 40 g per week, 
confirmed by at least two physicians and close family members. All subjects had a normal serum 
albumin level, prothrombin time, and renal function. To minimize the effects of protein-calorie 
malnutrition and catabolism from cirrhosis, all patients were Childs Class A. None of the patients 
were using thiazolidinediones. Secondary causes of steatohepatitis and other causes of liver 
disease were excluded by appropriate serological and biochemical tests. The study protocol was 
approved by the Human Ethics Committee of the Western Sydney Area Health Service and the 
University of Turin and written informed consent was obtained. 
Pathology. 
Liver tissues were stained with hematoxylin-eosin, reticulin, and Gomori trichrome stains and 
scored by an experienced hepatopathologist. The diagnosis of NASH was made according to the 
method of Brunt et al.2 Necroinflammatory activity was graded from 0-3 and fibrosis stage from 0-
4.19 A precise liver fat percentage was determined by morphometric analysis of liver core tissue 
and stained using Gomori trichrome. Slides were examined and photographed using a Leica DMLB 
microscope with a Spot RT camera (Leica Microsystems, Wetzlar Germany). For each biopsy 
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images that covered the entire liver core at 40× power were obtained to quantitate fat. Images 
were then analyzed using ImageJ software (ImageJ, NIH, Bethesda, MD20) and the quantity of fat 
determined as a percentage of the total liver core. Fat quantitated by this method has been shown 
to correlate highly with liver fat as determined by magnetic resonance spectroscopy and thus is 
reflective of larger volumes of liver tissue.21 
Clinical and Laboratory Evaluation. 
A complete physical examination was performed on each subject on the day of liver biopsy. 
Anthropometric evaluation included measures of BMI and central obesity (waist and hip 
circumferences and waist-hip ratio [WHR]). On the morning of liver biopsy, venous blood samples 
were drawn after an overnight 12-hour fast to determine the levels of serum alanine 
aminotransferase (ALT), bilirubin, albumin, total cholesterol, triglycerides, glucose, insulin, and 
adiponectin. Serum insulin was determined by a radioimmunoassay technique (Phadeseph Insulin 
RIA; Pharmacia and Upjohn Diagnostics, Uppsala, Sweden). Serum adiponectin and leptin levels 
were measured in duplicate by enzyme-linked immunosorbent assays (Quantikine ELISA; R&D 
Systems, Minneapolis, MN, and Diagnostic Systems Laboratories, Webster, TX). All additional 
biochemical tests were performed using conventional automated analyzers within the Department 
of Clinical Chemistry at Westmead Hospital and the University of Turin. Insulin resistance was 
calculated by the homeostasis model (HOMA-IR) using the formula: HOMA-IR = fasting insulin 
(mU/L) × plasma glucose (mmol/L)/22.5.22 
Immunohistochemistry. 
Formalin-fixed, paraffin-embedded 4-μ sections were dewaxed, subjected to antigen retrieval 
using 10 mM sodium citrate buffer, pH 6.0, and treated with DAKO block. Endogenous peroxidase 
activity was blocked with 0.6% H2O2 for 15 minutes, followed by treatment with an avidin/biotin 
blocking kit (Vector Laboratories). Sections were then stained overnight with adiponectin (Clone 
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19F1, Abcam), phospho-activated protein kinase (p-AMPK; Thr172, clone 40H9), and phospho-
acetyl-CoA carboxylase (p-ACC; Ser79, antibody #3661) from Cell Signaling and detected with 
antimouse DAKO Envision or biotin labeled goat antirabbit antibodies (ab6012) and subsequent 
streptavidin horseradish peroxidase. The site of the antigen was visualized with 3,3′-
diaminobenzidine treatment and counterstained with hematoxylin. The specificity of staining was 
confirmed by positive controls as previously published23 and negative controls with absent 
primary antibody. 
Western Blot and Cell Culture. 
3T3-L1 cells were maintained as subconfluent cultures in Dulbecco's modified Eagle's medium 
(DMEM) supplemented with 10% fetal calf serum (FCS). Postconfluent 3T3-L1 cells were treated 
with 220 nM dexamethasone, 100 ng/ml biotin, 1.4 mM insulin, and 500 mM 3-isobutyl-1-
methylxanthine for 3 days, followed by incubation with 1.4 mM insulin for 2 days and then 
maintained for a further 4 days in DMEM containing 10% FCS. Cells were washed once and treated 
with fexaramine (a generous gift from Prof. Ronald Evans, Salk Institute, La Jolla, CA) or 
taurolithocholic acid for 24 hours. Conditioned media were collected, precipitated with 
trichloroacetic acid, pelleted, washed twice with acetone, air-dried, resuspended in reducing 
Laemmli buffer, and heated to 95°C for 5 minutes. Proteins were separated by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and western blotting then performed and 
membranes probed with anti-adiponectin (Affinity BioReagents) and anti-complement C3 (Pierce) 
antibodies. 
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Serum Bile Acid Measurement. 
Individual serum bile acids were quantified by high-performance liquid chromatography-mass 
spectrometry (LC/MS) using authentic bile acid standards and deuterated internal standards as 
described.24 The detection limit for individual bile acids was 10 to 50 nmol/L. 
Statistical Analysis. 
Statistical analysis was carried out using SPSS v. 16.0 (IBM, Armonk, NY). Results are reported as 
mean ± standard deviation (SD) or frequency (percentage) as appropriate. The strength of 
association between continuous variables was reported using Spearman rank correlations. 
Student's t tests were used to compare means of continuous variables and P < 0.05 was 
considered significant throughout. Univariate analysis of variance (ANOVA) was used to examine 
factors associated with increasing increments of hepatic fat, as this was a categorical variable with 
multiple endpoints. Multiple ordinal regression analysis was carried out to determine which 
factors were significant on ANOVA, remained independent predictors for hepatic fat when 
adjusted for clinically relevant variables such as BMI, WHR, leptin, fibrosis stage, and HOMA-IR. 
Binary logistic regression with stepwise removal of variables was used to determine the 
independent associations of almost complete hepatic fat loss. Input variables included those 
significant on univariate analysis and clinically relevant variables such as BMI, WHR, leptin, 
bilirubin, platelets, and HOMA-IR. 
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Results 
The baseline characteristics of the 119 patients studied, 54 with early NASH (F0-1) and 65 with 
advanced NASH (F3-4) are listed in Table 1. Forty-three percent of patients with advanced NASH 
had cirrhosis and just under half were males. When compared to those with early NASH, the 
advanced NASH patients were older, more insulin-resistant, and had higher WHR and prothrombin 
time (P < 0.05 for all). There was no difference for the two groups in overall BMI, serum leptin, or 
liver fat percentage. Adiponectin levels were not elevated in those with advanced fibrosis, 
compared to early disease, even when cirrhotics were considered alone (9.3 versus 8.9 μg/mL, P = 
0.7). 
Adiponectin Inversely Correlates with Hepatic Fat in Advanced NASH. 
The univariate correlates of hepatic fat and adiponectin are presented in Table 2. There was a 
significant inverse correlation between serum adiponectin levels and the extent of hepatic fat 
across the whole NASH cohort (r = −0.28, P < 0.01), driven by patients with advanced fibrosis (r = 
−0.40, P < 0.01). Thus, as hepatic fat declined adiponectin levels significantly increased. Patient age 
was also associated with hepatic fat, once again primarily in those with advanced, but not mild 
NASH. In patients with advanced NASH there was no association between liver fat and any of the 
other key metabolic variables such as BMI, WHR, HOMA-IR, or leptin. In contrast, in those with F0-
1 NASH, liver fat and adiponectin were significantly associated with insulin resistance as measured 
by HOMA-IR (r = 0.32, r = 0.36, P < 0.05). In advanced NASH, serum adiponectin had a significant 
positive correlation with increasing age, but consistent with previous reports, there was no 
association with HOMA-IR or markers of adiposity (table 2). 
To further elucidate the relationship between hepatic fat and adiponectin in advanced NASH, we 
subdivided patients based on 5% increments of hepatic fat as follows: >15% fat (n = 17), 10.1%-
15% (n = 13), 5.1%-10% (n = 18), 0%-5% (n = 17), and observed that adiponectin levels 
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progressively increased as hepatic fat declined. Indeed, for each 4 μg/mL increase in adiponectin 
there was an odds ratio (OR) of 2.0 (95% confidence interval [CI]: 1.3-3.0, P = 0.002) for a 5% 
reduction in hepatic fat (Fig. 1, Table 3). BMI, WHR, HOMA-IR, fibrosis stage, and leptin were not 
predictive of changes in hepatic fat. Adiponectin, along with increasing age, were the only 
independent predictors of reducing hepatic fat by multiple ordinal regression, even when HOMA-
IR, WHR, fibrosis stage, leptin, and BMI were considered (Table 3; OR 1.6, 95% CI: 1.1-2.6, P = 
0.03). 
High Serum Adiponectin Is the Strongest Predictor of Burnt-Out NASH. 
We next evaluated the associations with almost complete hepatic fat loss (<5% fat), so called 
burnt-out NASH, in patients with advanced disease. In this subgroup of 17 patients (26% of cohort) 
the highest adiponectin was seen, with mean levels of 12.1 as compared to 7.4 μg/mL in the 
remaining patients (P = 0.001). The only other factor associated with burnt-out NASH was 
increasing age, whereas interestingly, a nonsignificant trend to higher bilirubin was also noted 
(Supporting Table 1). When evaluated in a logistic regression model, adiponectin remained an 
independent predictor of almost complete hepatic fat loss, even when controlled for these factors 
(Table 4). 
Serum Adiponectin Correlates with Hepatic Adiponectin Protein Activity. 
The described results strongly suggested an association between elevated serum adiponectin and 
hepatic fat loss; however, causality cannot be inferred. Adiponectin, in part, signals through 
phosphorylation of AMPK and ACC to reduce lipogenesis. To corroborate our data, we therefore 
next examined for evidence of a functional consequence of elevated circulating adiponectin by 
immunostaining for p-AMPK, p-ACC, and adiponectin in liver biopsies from patients with advanced 
NASH. In patients with high adiponectin and low fat (and consistent with our hypothesis), there 
was intense adiponectin staining and an increase in granular and cytoplasmic p-AMPK and p-ACC 
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staining. In contrast, those with low adiponectin and high fat had less intense adiponectin staining 
and absent or minimal staining for p-AMPK and p-ACC (Fig. 2). 
Serum Bile Acids Correlate with Serum Adiponectin Levels. 
The above observations suggest that increased adiponectin is associated with hepatic fat loss and 
further that serum adiponectin in late-stage NASH has downstream signaling effects that could 
mediate liver fat loss. However, as circulating adiponectin is produced by adipose tissue, we 
therefore hypothesized that in late-stage NASH the liver must signal to the adipocyte to mediate 
adiponectin synthesis. Bile acids are the most sensitive marker of liver injury, are increased with 
progressive liver fibrosis,25 and are also known to modulate adipocyte behavior.26 In Table 4 we 
have shown a nonsignificant trend to higher bilirubin, which closely parallels elevations in serum 
bile acids. We therefore measured the serum concentrations of individual bile acids in a subset of 
28 patients with advanced NASH by LC/MS. By linear regression, levels of deoxycholic acid (DCA) 
and glycine conjugated DCA paralleled the increase in adiponectin (DCA: r = 0.51, P < 0.01, G-DCA: 
r = 0.49, P < 0.01), but not cholic acid (CA), chenodeoxycholic acid (CDCA), or ursodeoxycholic acid 
(UDCA). 
In a final experiment, to test the role of bile acids on adiponectin expression we treated 
differentiated 3T3-L1 adipocytes with fexaramine (FXR agonist) or taurolithocholic acid (TGR-5 
agonist) and examined the cell culture supernatant for adiponectin protein. We found that both 
fexaramine and taurolithocholic acid increased adiponectin protein secretion greater than 10-fold 
(Fig. 3). These data suggest that bile acids act directly to regulate adiponectin synthesis in 
adipocytes. 
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Discussion 
One of the most intriguing and unanswered questions in clinical hepatology concerns the 
observation that liver fat loss often accompanies advanced fibrosis and cirrhosis, something that 
delayed the linkage of NASH to cryptogenic cirrhosis for many years. In this study we show for the 
first time that alterations in serum adiponectin may provide an explanation for this phenomenon 
and suggest a novel mechanism by which this might occur (Fig. 4). In well-characterized patients 
with biopsy proven NASH, we show that (1) circulating adiponectin levels have an inverse 
correlation with hepatic fat content in those with advanced disease; (2) as hepatic fat declines 
with advanced fibrosis, adiponectin levels progressively rise, independent of its usual metabolic 
associations, viz. insulin resistance, leptin, BMI, and WHR; (3) elevated serum adiponectin is 
significantly and independently associated with almost complete hepatic fat loss, so-called “burnt-
out” NASH, even when controlled for patient age and markers of liver synthetic dysfunction; (4) 
circulating adiponectin in advanced NASH is associated with activation of its downstream signaling 
in the liver; (5) bile acids in late-stage NASH that are ligands for the bile acid receptors FXR and 
TGR527 are elevated in patients; and finally (6) that this elevation in circulating bile acids may be 
responsible for the secretion of adiponectin by adipocytes in advanced liver disease (Fig 4). 
Adiponectin is a key player in the pathogenesis of NASH-related steatosis, with an intimate 
association between hypoadiponectinemia, increasing steatosis grade, and the transformation 
from simple steatosis to NASH.16, 28 Acting predominantly by way of the hepatic adiponectin 
receptor 2 (AdipoR2), elevated levels of adiponectin are profoundly antisteatotic, an effect 
mediated by stimulation of PPAR-α with an increase in fatty acid β-oxidation, and inhibition of 
fatty acid synthesis by way of SREBP-1c.13 It is now well established that adiponectin is elevated in 
advanced liver disease and cirrhosis of any cause, although most evidence exists for viral, 
autoimmune, cholestatic, and alcohol-related disease.15, 17, 18 A single report has directly linked 
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NASH cirrhosis with elevated adiponectin,29 but others have included numerous patients with 
cryptogenic cirrhosis, in whom NASH is highly probable.5, 6 
In the present study, adiponectin levels were not significantly elevated in those with advanced-
stage NASH fibrosis/cirrhosis when compared to those with early disease. One might have 
expected the levels to be lower in patients with advanced NASH who were more insulin resistant 
and obese than those with early disease, but it is established that adiponectin levels in cirrhosis do 
not correlate with insulin resistance, dyslipidemia, or obesity.17, 18 The unaltered levels of 
adiponectin in late compared to early disease is in part a deliberate consequence of our strict 
selection criteria, wherein we excluded (1) all patients with markers of liver synthetic dysfunction 
such as abnormal prothrombin time, albumin, or bilirubin, and (2) those with Child's B and C 
cirrhosis. Thus, we were able to exclude elevations due to these confounders known to be 
associated with increased adiponectin, and further strengthen our hypothesis.17, 18 Adiponectin 
levels are also lower in patients with nonalcoholic fatty liver disease (NAFLD) compared to other 
liver diseases29 and levels decline further with increasing necroinflammation and fibrosis. Thus, 
the finding of similar adiponectin levels for our two groups is in keeping with a relative elevation of 
adiponectin, similar to that seen in other forms of cirrhosis. Taken together, these findings suggest 
that physiological regulation of adiponectin is dramatically altered in patients with advanced-stage 
liver disease compared to the situation in healthy volunteers, diabetes, or early liver disease.16, 30 
A number of mechanisms have been hypothesized to explain the relative elevation in adiponectin 
with progressive fibrosis, including an imbalance between adiponectin production and hepatic 
extraction,18, 31 a protective antiinflammatory mechanism in the chronic inflammatory state of 
cirrhosis,18 and an increase in true hepatocyte or hepatic stellate cell adiponectin production.17, 32 
Because the highest levels of adiponectin are seen in patients with advanced cholestatic liver 
disease, reduced biliary excretion of adiponectin may also be important.15, 17, 33 This theory is 
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supported by bile duct ligation studies in mice where dramatic increases in serum adiponectin 
were seen over time, and the detection of adiponectin in the bile of human subjects with severe 
cholestasis.15 None of the patients included in this study were severely catabolic or clinically had 
cholestasis (elevations in bilirubin), which raised the intriguing question as to why adiponectin 
would be elevated in our cohort and whether there could be a link between hepatocyte 
dysfunction and adiponectin production by adipose tissues. 
Bile acids are sensitive markers of liver dysfunction, play an important part in metabolic 
signaling,34, 35 and are well documented to be increased with advancing liver fibrosis.25 Hence, our 
observation that elevation in specific circulating bile acids may be responsible for the secretion of 
adiponectin by adipocytes was not altogether surprising. If our hypothesis is correct, then 
hepatocyte-adipocyte crosstalk mediated by bile acids and their receptors could explain our 
observations and drive adipocyte-mediated adiponectin production in advanced liver disease. Bile 
acid receptors such as FXR and TGR-5 are expressed in adipose tissue and their activation has been 
associated with improved insulin sensitivity and metabolic homeostasis.26, 36 Thus, our final in vitro 
data demonstrating robust up-regulation of adiponectin secretion in adipocytes treated with bile 
acid receptor agonists provides direct confirmation of this hypothesis. 
A number of alternate mechanisms have previously been proposed to explain hepatic fat loss in 
advanced NASH, but none have been examined in any detail in a NASH cohort. Cirrhosis is a 
chronic inflammatory, catabolic state characterized by increased resting energy expenditure, 
cachexia, and elevated plasma levels of proinflammatory cytokines such as interleukin (IL)-6, 
tumor necrosis factor alpha (TNF-α), and IL-1.12, 18 Additionally, there is increased utilization of 
systemic fat stores for energy generation,12 and hepatic fat may be similarly affected. All of these 
changes tend to be most marked in the end stages of cirrhosis and would not explain the fat loss 
that is seen in well-compensated patients such as those in our study, or those in previous reports.7 
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Furthermore, in reports where paired biopsy samples have been studied patients with hepatic fat 
loss tended to have gained, rather than lost weight.7, 37, 38 Circulatory changes that occur in 
advanced liver disease have also been implicated in hepatic fat loss. It is known, for example, that 
focal fatty sparing in steatotic livers can result from aberrant portal venous drainage, which in turn 
reduces hepatocyte exposure to insulin and triglycerides.39 Similarly, shunting between the portal 
and systemic circulations in advanced liver disease has been shown to alter hepatocyte exposure 
not only to insulin and triglycerides, but also to free fatty acids, lipoproteins, and precursors of 
gluconeogenesis.10 Changes at a cellular level such as a loss of sinusoidal fenestrations,11 altered 
mitochondrial function,8 or liver repopulation with oval cells40 have also been suggested to 
reduce hepatic fat, although the data to support any of these theories remain scant, and we 
believe less plausible in the present cohort. Intriguingly, there is increasing evidence to suggest 
hepatic fat loss also occurs in advanced hepatitis C virus (HCV)41 and the phenomena is likely to 
be replicated in the late stages of all steatotic liver disease. Adiponectin is inversely associated 
with steatosis in genotype 4 HCV,42 but is elevated in all genotypes once cirrhosis is established,15, 
18 Hence, one could speculate that adiponectin may also be responsible for hepatic fat loss that is 
seen with advanced HCV. 
One limitation of this study relates to the cross-sectional nature of the data and therefore the 
difficulty in inferring cause and effect. Ideally one would like to show longitudinal changes in both 
liver fat and adiponectin levels over many timepoints to be sure the two were directly related. The 
invasive nature of liver biopsy, logistic and ethical constraints, and the numerous additional 
confounding interactions that occur over time mean this approach is not feasible. Hence, we 
analyzed our data in a number of ways to strengthen and validate the association between 
adiponectin and hepatic fat loss. We showed the association to hold true for quintiles of hepatic 
fat and for those with almost total fat loss and, importantly, that it was independent of key 
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metabolic variables, patient age, and liver dysfunction. We also confirmed that serum adiponectin 
was correlated with hepatic adiponectin protein activity based on liver blots for downstream 
enzymes. Finally, in animal studies of NASH and in carbon tetrachloride-induced liver fibrosis 
exogenous adiponectin administration reduces hepatic steatosis, an expected consequence of the 
known physiological actions of this protein.13 
In conclusion, circulating adiponectin levels in compensated late-stage NASH are significantly 
associated with hepatic fat loss, independent of metabolic or liver dysfunction. Our data in toto 
support the notion of bile acid-mediated hepatocyte-adipocyte crosstalk, leading to elevations of 
circulating adiponectin, which in turn may in part be responsible for the paradox of burnt-out 
NASH. 
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Figure Legends 
Figure 1. Serum adiponectin levels compared to 5% increments in hepatic fat. Low serum 
adiponectin levels are seen in patients with high hepatic fat. As the hepatic fat percent declines 
there is a significant increase in adiponectin levels. 
Figure 2. Immunohistochemistry: Liver sections were stained with p-ACC, p-AMPK, and 
adiponectin to demonstrate adiponectin activity. (B,C) Absent or minimal staining for p-AMPK and 
p-ACC in patients with low serum adiponectin and high fat. (E,F) Increased cytoplasmic granular 
staining with pericanilicular association for p-AMPK and p-ACC in patients with high serum 
adiponectin and low fat. (H,J) Increased intensity of adiponectin staining in patients with high 
adiponectin and low fat (J) compared to those with low adiponectin and high fat (H). (A,D,G,I) 
Negative controls with absent primary antibody (all images 400×). 
Figure 3. FXR and TGR-5 receptor agonists induce adiponectin secretion by adipocytes in vitro. 
Reducing SDS electrophoresis of total adiponectin protein after (A), fexaramine (Fex) and (B), 
taurolithocholic acid (T-LCA) at the indicated concentrations (μM). (C) Loading control 
(Complement C3). 
Figure 4. Adiponectin is elevated in advanced liver disease and is associated with steatosis 
resolution in NASH. In health, adiponectin is regulated by metabolic factors such as IR, adiposity, 
and dyslipidemia, but these are not important in advanced liver disease. We propose that 
hepatocyte-adipocyte crosstalk by way of bile acids may directly stimulate adiponectin production.  
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Table 1. Baseline Characteristics of the Patients with NASH 
Baseline Characteristics NASH F0-1 (n=54) NASH F3-4 (n=65) P-value 
Cirrhosis — 28 (43%) — 
Male gender 31 (57%) 32 (49%) 0.3 
Age (years) 47.9 (11.6) 53 (12.8) 0.03 
BMI (kg/m2) 30.3 (4.6) 31.9 (5.6) 0.09 
Waist-hip ratio 0.97 (0.08) 1.01 (0.07) 0.02 
HOMA-IR 4.9 (3.1) 6.9 (4.0) <0.01 
ALT (IU/mL) 78.4 (44.3) 77 (55) 0.9 
Bilirubin (mmol/L) 14.1 (7.8) 14.7 (6.7) 0.6 
Platelets (x109/mL) 266 (66) 199 (80) <0.01 
Prothrombin Time (seconds) 12 (1.0) 14 (3.2) <0.01 
Adiponectin (μg/mL) 8.9 (6.0) 8.6 (5.2) 0.8 
Leptin (ng/mL) 30.7 (26.1) 40.1 (33.3) 0.1 
Liver fat % 9.7 (6.7) 10.4 (7.1) 0.6 
 
Variables are reported as frequency (percentage) or mean (SD) as appropriate. 
BMI; body mass index, WHR; waist hip ratio, HOMA-IR; homeostasis model assessment of insulin 
resistance, ALT; alanine transaminase.  
24 
 
Table 2. Univariate Correlations of Hepatic Fat and Serum Adiponectin Levels in Mild and 
Advanced NASH 
  Adiponectin Leptin WHR BMI Age HOMA-IR ALT Bilirubin Platelets 
NASH Cohort (n=119)                   
 Hepatic fat % −0.28** 0.05 0.04 0.20 −0.33** 0.15 0.14 −0.03 0.10 
 Adiponectin μg/mL — 0.02 0.10 −0.11 0.17 −0.23* −0.06 0.10 0.01 
Mild NASH (F0-1, n=54)                   
 Hepatic fat % −0.13 0.06 0.04 0.10 −0.19 0.32* 0.05 −0.05 0.09 
 Adiponectin μg/mL — −0.10 −0.10 −0.21 −0.03 −0.36** −0.05 0.19 0.17 
Advanced NASH (F3-4, n=65)                   
 Hepatic fat % −0.40** 0.12 0.04 −0.04 −0.45** 0.03 0.21 −0.04 0.15 
 Adiponectin μg/mL — 0.12 0.16 0.01 0.33** −0.10 −0.10 0.04 
 
 
* P < 0.05, 
** P < 0.01, WHR; waist hip ratio, BMI; body mass index, HOMA-IR; homeostasis model 
assessment of insulin resistance, ALT; alanine transaminase. 
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Table 3. Multivariate Correlations of Hepatic Fat in Advanced NASH 
                                     Unadjusted        Best Fitting Model* 
                                Odds Ratio (95% CI)         P- value       Odds Ratio (95% CI)  P- value 
 
Hepatic fat grade                                                                                                                                            
(5% increments)         
Adiponectin                          2.0 (1.3–3.0)               0.002              1.6 (1.1–2.6)                   0.03                                          
(per 4 μg/L increase) 
Age (per 5-year increase)      1.5 (1.2–1.8)               0.001              1.4 (1.1–1.7)      0.002 
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Supporting Table 1. Univariate correlates for burnt-out NASH (<5% fat)  
 
Factor 
Hepatic fat < 5% 
(n=17) 
Hepatic fat ≥ 5% 
(n=48) 
P-value 
Adiponectin (ug/mL) 12.1 (5.8) 7.4 (4.4) 0.001 
Age (years) 58.1 (11.3) 50.1 (12.9) 0.05 
Bilirubin (mmol/L) 17.6 (9.4) 13.7 (5.2) 0.08 
Male gender  8 (47%) 24 (50%) 0.84 
BMI  (kg/m2) 32.3 (6.8) 31.8 (5.2) 0.79 
Waist-Hip Ratio 0.99 (0.07) 1.01 (0.07) 0.29 
HOMA-IR  6.2 (3.9) 7.0 (4.2) 0.48 
ALT  (IU/mL) 80 (87) 76 (39) 0.76 
Platelets (x109/mL) 176 (46) 207 (88) 0.38 
Prothrombin Time 
(seconds) 
13.4 (4.4) 13.7 (2.8) 0.76 
Leptin (ng/mL) 39.8 (37.4) 40.6 (32.2) 0.94 
Values are expressed as mean (SD) or frequency (%) as appropriate 
 
  
